UCB Ventures and GV returned for the neurodegenerative, neuromuscular and retinal disease drug developer's series B round.

Drug release technology developer Rani has now raised $211m in all, from investors including GV, Novartis, Ping An Ventures, KPC, AstraZeneca and Stevanato.

Kissei Pharmaceutical has become the cancer immunotherapy developer's first corporate investor, in a series D round bringing its overall funding to $93.5m.

Jafco has led a round of undisclosed size for the All About, Nippon Life, KLab and Credit Saison-backed teleconsultation technology developer, taking its total funding to nearly $20m.

The neurodegenerative disorder drug developer has emerged from stealth to commercialise Howard Hughes Medical Institute research.

Novo is set to exit the cancer drug developer in a purchase by another of its shareholders, Boehringer Ingelheim, that could reach $1.43bn.

The medical services app developer welcomed Baidu Capital aboard in a series C-plus round that represents its second nine-figure round.

Eli Lilly, Novartis Venture Fund and AbbVie Ventures are among the contributors to a series A round disclosed as the neurodegenerative disorder drug developer emerged from stealth.

Shares in the antibody discovery platform developer, advancing UBC research, opened at more than three times their IPO price to net it a valuation topping $15bn.

Spun out of University of Côte d’Azur and Inserm, InnoSkel expects to fund clinical work to address a form of skeletal dysplasia that causes dwarfism.